A molecular farming entity, in the UK, specializing in the production of egg protein through genetically modified potato crops has transitioned from greenhouse operations to field-scale cultivation. This move marks the inaugural widespread planting of crops utilizing the company's unique metabolic engineering techniques. The potatoes are engineered to produce and accumulate high protein levels within their tubers, which are then processed into a functional protein powder.
The anticipated yield from the current crop is projected at approximately three tons, a substantial increase from the initial yield of several tens of kilograms. This scale-up aims to facilitate large-scale cultivation of select varieties showing promise in greenhouse trials, test a broad spectrum of new genotypes for protein accumulation efficiency, and reaffirm the performance of chosen genotypes under field conditions.
Maya Sapir-Mir, CEO of PoLoPo, expressed enthusiasm about the progression from lab to greenhouse and now to field cultivation as a significant advancement for both the company and the molecular farming sector. The Eshkol region in southern Israel, known for its potato cultivation, serves as the location for PoLoPo's field trials, in collaboration with a local veteran grower.
Using advanced metabolic engineering, PoLoPo transforms potato plants into biofactories for protein production, with the end goal of creating a functional protein powder. The company targets ovalbumin as its primary product, offering an alternative amid rising egg prices and supply chain challenges. Additionally, PoLoPo plans to produce patatin, a native potato protein. Regulatory approval from the USDA is anticipated shortly, which will enable US partnership and cultivation endeavors.
Founded in 2022 by experts in plant genetics and protein expression, PoLoPo has garnered recognition and funding from leading entities in the food-tech investment sphere.
Source: British Potato